{"id":"https://openalex.org/W2139095422","doi":"https://doi.org/10.1161/atvbaha.115.306245","title":"An In Vitro Cynomolgus Vascular Surrogate System for Preclinical Drug Assessment and Human Translation","display_name":"An In Vitro Cynomolgus Vascular Surrogate System for Preclinical Drug Assessment and Human Translation","publication_year":2015,"publication_date":"2015-08-21","ids":{"openalex":"https://openalex.org/W2139095422","doi":"https://doi.org/10.1161/atvbaha.115.306245","mag":"2139095422","pmid":"https://pubmed.ncbi.nlm.nih.gov/26293464"},"language":"en","primary_location":{"id":"doi:10.1161/atvbaha.115.306245","doi":"https://doi.org/10.1161/atvbaha.115.306245","is_oa":true,"landing_page_url":"https://doi.org/10.1161/atvbaha.115.306245","pdf_url":"https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.115.306245","source":{"id":"https://openalex.org/S3485792","display_name":"Arteriosclerosis Thrombosis and Vascular Biology","issn_l":"1079-5642","issn":["1079-5642","1524-4636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arteriosclerosis, Thrombosis, and Vascular Biology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.115.306245","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063582275","display_name":"Banumathi K. Cole","orcid":"https://orcid.org/0000-0003-0976-2610","observed_orcids":["https://orcid.org/0000-0003-0976-2610"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Banumathi K. Cole","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000972663","display_name":"Michael B. Simmers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael B. Simmers","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036323568","display_name":"Ryan E. Feaver","orcid":"https://orcid.org/0000-0003-3709-4971","observed_orcids":["https://orcid.org/0000-0003-3709-4971"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan Feaver","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013494340","display_name":"Charles W. Qualls","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles W. Qualls","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003106812","display_name":"Maria Sol Collado","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Sol Collado","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078132051","display_name":"Erica Berzin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erica Berzin","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042414938","display_name":"Robert A. Figler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert A. Figler","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041297153","display_name":"Andrew W. Pryor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew W. Pryor","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112006373","display_name":"Mark J. Lawson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Lawson","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074405433","display_name":"Aaron J. Mackey","orcid":"https://orcid.org/0000-0003-4734-5324","observed_orcids":["https://orcid.org/0000-0003-4734-5324"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron Mackey","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068128505","display_name":"David R. Manka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Manka","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056729984","display_name":"Brian R. Wamhoff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian R. Wamhoff","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110739641","display_name":"James R. Turk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James R. Turk","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113452593","display_name":"Brett R. Blackman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]},{"id":"https://openalex.org/I4210122436","display_name":"HemoShear (United States)","ror":"https://ror.org/02s4ke886","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brett R. Blackman","raw_affiliation_strings":["From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.),","institution_ids":["https://openalex.org/I4210122436"]},{"raw_affiliation_string":"Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.984,"has_fulltext":true,"cited_by_count":9,"citation_normalized_percentile":{"value":0.74729448,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"35","issue":"10","first_page":"2185","last_page":"2195"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12955","display_name":"Atherosclerosis and Cardiovascular Diseases","score":0.9423999786376953,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12955","display_name":"Atherosclerosis and Cardiovascular Diseases","score":0.9423999786376953,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.03310000151395798,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.016699999570846558,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.7710000276565552},{"id":"https://openalex.org/keywords/pleiotropy","display_name":"pleiotropy","score":0.7940000295639038},{"id":"https://openalex.org/keywords/atherosclerosis","display_name":"atherosclerosis","score":0.7940000295639038},{"id":"https://openalex.org/keywords/pro-inflammatory-cytokines","display_name":"inflammatory cytokines","score":0.6650000214576721},{"id":"https://openalex.org/keywords/gene-expression-profiling","display_name":"gene expression profiling","score":0.765999972820282},{"id":"https://openalex.org/keywords/off-target-effects","display_name":"off-target effects","score":0.7110000252723694},{"id":"https://openalex.org/keywords/thrombosis","display_name":"thrombosis","score":0.9399999976158142},{"id":"https://openalex.org/keywords/ethanol-degradation","display_name":"ethanol degradation","score":0.5130000114440918},{"id":"https://openalex.org/keywords/human-translation","display_name":"human translation","score":0.5619999766349792}],"concepts":[{"id":"https://openalex.org/C149364088","wikidata":"https://www.wikidata.org/wiki/Q185917","display_name":"Translation (biology)","level":4,"score":0.6534048914909363},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6311707496643066},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.553842306137085},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.505374014377594},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4735157787799835},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.33662915229797363},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.21141937375068665},{"id":"https://openalex.org/C105580179","wikidata":"https://www.wikidata.org/wiki/Q188928","display_name":"Messenger RNA","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002478","descriptor_name":"Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008077","descriptor_name":"Lipoproteins, LDL","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D008077","descriptor_name":"Lipoproteins, LDL","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008252","descriptor_name":"Macaca fascicularis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008955","descriptor_name":"Models, Cardiovascular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009131","descriptor_name":"Muscle, Smooth, Vascular","qualifier_ui":"Q000166","qualifier_name":"cytology","is_major_topic":false},{"descriptor_ui":"D009131","descriptor_name":"Muscle, Smooth, Vascular","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013045","descriptor_name":"Species Specificity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D042783","descriptor_name":"Endothelial Cells","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D066298","descriptor_name":"In Vitro Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1161/atvbaha.115.306245","doi":"https://doi.org/10.1161/atvbaha.115.306245","is_oa":true,"landing_page_url":"https://doi.org/10.1161/atvbaha.115.306245","pdf_url":"https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.115.306245","source":{"id":"https://openalex.org/S3485792","display_name":"Arteriosclerosis Thrombosis and Vascular Biology","issn_l":"1079-5642","issn":["1079-5642","1524-4636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arteriosclerosis, Thrombosis, and Vascular Biology","raw_type":"journal-article"},{"id":"pmid:26293464","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26293464","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arteriosclerosis, thrombosis, and vascular biology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1161/atvbaha.115.306245","doi":"https://doi.org/10.1161/atvbaha.115.306245","is_oa":true,"landing_page_url":"https://doi.org/10.1161/atvbaha.115.306245","pdf_url":"https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.115.306245","source":{"id":"https://openalex.org/S3485792","display_name":"Arteriosclerosis Thrombosis and Vascular Biology","issn_l":"1079-5642","issn":["1079-5642","1524-4636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arteriosclerosis, Thrombosis, and Vascular Biology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.7599999904632568,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320309558","display_name":"Wake Forest University","ror":"https://ror.org/0207ad724"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2139095422.pdf","grobid_xml":"https://content.openalex.org/works/W2139095422.grobid-xml"},"referenced_works_count":47,"referenced_works":["https://openalex.org/W1878249365","https://openalex.org/W1964471078","https://openalex.org/W1970504214","https://openalex.org/W1978139625","https://openalex.org/W1986858103","https://openalex.org/W1988093420","https://openalex.org/W2001499130","https://openalex.org/W2008217969","https://openalex.org/W2016875014","https://openalex.org/W2017357456","https://openalex.org/W2021104818","https://openalex.org/W2028103879","https://openalex.org/W2033606744","https://openalex.org/W2037859009","https://openalex.org/W2047362606","https://openalex.org/W2059993923","https://openalex.org/W2066533995","https://openalex.org/W2070114011","https://openalex.org/W2077756722","https://openalex.org/W2082732641","https://openalex.org/W2087701027","https://openalex.org/W2090372317","https://openalex.org/W2103802452","https://openalex.org/W2113620629","https://openalex.org/W2114197087","https://openalex.org/W2121822802","https://openalex.org/W2122035828","https://openalex.org/W2125589683","https://openalex.org/W2126564019","https://openalex.org/W2131222777","https://openalex.org/W2133421184","https://openalex.org/W2133546870","https://openalex.org/W2138241559","https://openalex.org/W2141725015","https://openalex.org/W2144190812","https://openalex.org/W2147919276","https://openalex.org/W2151731574","https://openalex.org/W2154177618","https://openalex.org/W2156943914","https://openalex.org/W2157626278","https://openalex.org/W2159789948","https://openalex.org/W2161092372","https://openalex.org/W2163625494","https://openalex.org/W2164375593","https://openalex.org/W2165321272","https://openalex.org/W2166046639","https://openalex.org/W2168569594"],"related_works":["https://openalex.org/W1776725782","https://openalex.org/W2138432239","https://openalex.org/W2054639223","https://openalex.org/W2064962005","https://openalex.org/W2164103331","https://openalex.org/W2056530140","https://openalex.org/W2093229305","https://openalex.org/W4393022512","https://openalex.org/W1942959610","https://openalex.org/W1964646847"],"abstract_inverted_index":{"OBJECTIVES:":[0],"The":[1,159],"predictive":[2],"value":[3],"of":[4,29,35,49,65,89,117,139,172],"animal":[5],"and":[6,70,108,155,168,179],"in":[7,37,46,67,185],"vitro":[8,38,68],"systems":[9,73],"for":[10,16,145],"drug":[11,27],"development":[12,34],"is":[13,22,91],"limited,":[14],"particularly":[15],"nonhuman":[17],"primate":[18],"studies":[19],"as":[20],"it":[21],"difficult":[23,92],"to":[24,74,93,106],"deduce":[25],"the":[26,33,45,63,66,84,87,96,104,115,166,173],"mechanism":[28,88],"action.":[30],"We":[31,61],"describe":[32],"an":[36],"cynomolgus":[39,71,160],"macaque":[40],"vascular":[41,72,121,161],"system":[42,162],"that":[43,110,119,142],"reflects":[44],"vivo":[47],"biology":[48,171],"healthy,":[50],"atheroprone,":[51],"or":[52],"advanced":[53],"inflammatory":[54,125,169],"cardiovascular":[55],"disease":[56],"conditions.":[57],"APPROACH":[58],"AND":[59],"RESULTS:":[60],"compare":[62],"responses":[64],"human":[69,85,174],"4":[75],"statins.":[76],"Although":[77],"statins":[78,107,112],"exert":[79],"beneficial":[80],"pleiotropic":[81],"effects":[82],"on":[83],"vasculature,":[86,175],"action":[90],"investigate":[94],"at":[95],"tissue":[97],"level.":[98],"Using":[99],"RNA":[100],"sequencing,":[101],"we":[102,133],"quantified":[103],"response":[105],"report":[109],"most":[111],"significantly":[113],"increased":[114],"expression":[116],"genes":[118],"promote":[120],"health":[122],"while":[123],"suppressing":[124],"cytokine":[126],"gene":[127],"expression.":[128],"Applying":[129],"computational":[130],"pathway":[131],"analytics,":[132],"identified":[134],"statin-regulated":[135],"biological":[136],"themes,":[137],"independent":[138],"cholesterol":[140],"lowering,":[141],"provide":[143],"mechanisms":[144],"off-target":[146],"effects,":[147],"including":[148,176],"thrombosis,":[149],"cell":[150],"cycle":[151],"regulation,":[152],"glycogen":[153],"metabolism,":[154],"ethanol":[156],"degradation.":[157],"CONCLUSIONS:":[158],"described":[163],"herein":[164],"mimics":[165],"baseline":[167],"regional":[170],"statin":[177],"responsiveness,":[178],"provides":[180],"mechanistic":[181],"insight":[182],"not":[183],"achievable":[184],"vivo.":[186]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}